

NEW JERSEY MEDICAL SCHOOL

NEW YORK CITY WORLD TB DAY: FROM EVIDENCE TO ACTION

MARCH 18, 2019
CME/CNE CERTIFIED ACTIVITY

Course Location

NYC Department of Health and Mental Hygiene 42-09 28th Street Long Island City, NY 11101

Jointly Provided By

The New Jersey Medical School Global Tuberculosis Institute at Rutgers, The State University of New Jersey and New York City Department of Health and Mental Hygiene

WHY COURSE IS NEEDED

As the incidence of tuberculosis continues to decline, maintaining clinical and public health expertise in TB is particularly challenging especially as the cases are more complex to diagnose and manage. Ongoing training and education are important for clinicians so they can develop and enhance skills in the diagnosis of TB, follow recommended treatment guidelines, and interact effectively with public health agencies.

COURSE DESCRIPTION & OVERALL GOAL

In commemoration of World TB Day, this conference will address the TB epidemic in New York City. Topics will include a review of local epidemiology, using data and genotyping towards the path of TB elimination, new guidelines for MDR TB, and TB and special populations.

COURSE REQUIREMENTS

In order to meet the learning objectives and receive continuing education credits, participants are required to attend the entire training and complete an evaluation. Participants will be asked to complete a follow-up evaluation within 1 month of the training.

WHO SHOULD ATTEND

This conference is open to physicians, nurses, public health staff, and other healthcare workers who manage patients at risk for or diagnosed with TB infection or disease.

OBJECTIVES

Upon completion of this conference, participants should be better able to:

- Recognize the epidemiology of tuberculosis in New York City to make informed decisions about outreach interventions and allocation of resources.
- Apply updated recommendations for testing and treating TB infection in pediatric patients with the goal of increasing treatment initiation and completion.
- Explain patient-centered care approaches for addressing the challenges of testing and treating TB in elderly patients with complex clinical and social issues.
- Outline approaches for the diagnosis, treatment, and management of drug resistant TB recognizing the global context and domestic perspectives for clinical and programmatic implications.

FACULTY LIST

Shama Ahuja, PhD, MPH

Director, Office of Surveillance and Epidemiology New York City Department of Health and Mental Hygiene, Bureau of TB Control

Claudia Buchanan, MSN, MPH, RN

Patient Care Manager

New York City Department of Health and Mental Hygiene, Bureau of TB Control

Joseph Burzynski, MD, MPH

Assistant Commissioner, Director

New York City Department of Health and Mental Hygiene, Bureau of TB Control

Caralee Caplan-Shaw, MD

Research Assistant Professor

NYC Health + Hospital/Bellevue

Andrea Cruz, MD, MPH

Research Chief, Pediatric Emergency Medicine

Texas Children's Hospital

Sneha Dedhia

Patient Advocate

Felicia Dworkin, MD

Deputy Director, Medical Affairs

New York City Department of Health and Mental Hygiene, Bureau of TB Control

Alfred Lardizabal, MD

Executive Director

Global Tuberculosis Institute

Shelly Malhotra, MA

Director, Market Access

Global Alliance for TB Drug Development

Herns Modestil, BS

Laboratory Coordinator

New York City Department of Health and Mental Hygiene, Bureau of TB Control

Masa Narita, MD

Director, TB Control Program, Public Health - Seattle & King County

Professor of Medicine, University of Washington

Neil W. Schluger, MD

Professor of Medicine, Epidemiology, and Environmental Health Science Chief, Division of Pulmonary, Allergy, and Critical Care Medicine Columbia University Medical Center

Crystal Simmons, BS

Field Services Manager

New York City Department of Health and Mental Hygiene, Bureau of TB Control

PLANNING COMMITTEE

Global Tuberculosis Institute

Anita Khilall, MPH - Director of Education & Training Amy Lewis, MPH, MCHES - Health Educator

New York City Department of Health and Mental Hygiene, Bureau of TB Control

Martha Alexander, MHS - Director of Education & Training

Eleanora Amoyaw, BS - CDC Public Health Associate

Elvy G. Barroso, PhD, MD, MSc, MS, MPH, RN - Professional Development Coordinator

Stephanie Michel, BA - CDC Public Health Associate

Shaila Rao, EdD, MPH - Director of Outreach

AGENDA

8:30 am	Registration/Breakfast
9:00 am	Tuberculosis Globally and Locally: Challenges and Progress
9:15 am	From Evidence to Action: Intensifying Efforts on Global, National, and Local TB
9:30 am	The State of TB in New York City, 2018
10:00 am	Break
10:15 am	TB Across the Lifespan Panel
10:20 am	TB in the Elderly
11:00 am	Case Presentation
11:30 am	Lessons Learned from Childhood TB in a Low-Incidence Setting
12:10 pm	Case Presentation
12:40 pm	Lunch
1:40 pm	Drug Resistant TB Panel
1:45 pm	MDR-TB Trial and Treatment Landscape
2:35 pm	Programmatic Implementation of Whole Genome Sequencing for TB in New York
3:00 pm	Break
3:15 pm	Use of Diagnostic Tests in the Clinical Management of Patients with Drug-Resistant TB
3:40 pm	Patient Perspective
4:20 pm	Closing Remarks

CONTINUING EDUCATION INFORMATION



In support of improving patient care, this activity has been planned and implemented by Rutgers Biomedical and Health Sciences and New York City Department of Health and Mental Hygiene. Rutgers Biomedical and Health Sciences is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for

the healthcare team.

PHYSICIANS: Rutgers Biomedical and Health Sciences designates this live activity for a maximum of 5.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

NURSES: This activity is awarded 5.5 contact hours (60-minute CH). Nurses should only claim those contact hours actually spent participating in the activity.

PEER REVIEW STATEMENT

In order to help ensure content objectivity, independence, and fair balance, and to ensure that the content is aligned with the interest of the public, Rutgers Biomedical and Health Sciences (RBHS) has resolved all potential and real conflicts of interest through content review by non-conflicted, qualified reviewers. This activity has been peer reviewed for relevance, accuracy of content and balance of presentation by Amy Lewis, MPH, MCHES and Anita Khilall, MPH.

DISCLOSURE DISCLAIMER

In accordance with the disclosure policies of RBHS and to conform with Joint Accreditation requirements and FDA guidelines, individuals in a position to control the content of this educational activity are required to disclose to the activity participants: 1) the existence of any relevant financial relationship with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients, with the exemption of non-profit or government organizations and non-health care related companies, within the past 12 months; and 2) the identification of a commercial product/device that is unlabeled for use or an investigational use of a product/device not yet approved.

Financial Disclosure

The following faculty and planning committee members have stated that they have no relevant financial relationships to disclose:

Shama Ahuja, PhD, MPH Martha Alexander, MHS Eleanora Amoyaw, BS Elvy G. Barroso, PhD, MD, MSc, MS, MPH, RN Claudia Buchanan, MSN, MPH, RN Joseph Burzynski, MD, MPH Caralee Caplan-Shaw, MD Andrea Cruz, MD, MPH Sneha Dedhia Felicia Dworkin, MD Anita Khilall, MPH Alfred Lardizabal, MD Amy Lewis, MPH, MCHES Shelly Malhotra Stephanie Michel, BA Herns Modestil, BS Masa Narita, MD Shaila Rao, EdD, MPH Neil W. Schluger, MD Crystal Simmons, BS

RBHS Center for Continuing and Outreach Education Staff Elizabeth Ward, MSJ, Executive Director has no relevant financial relationships to disclose.

Off-Label/Investigational Use Disclosure

The course will include a mention of the use of linezolid, clofazimine, delamanid, and fluoroquinolones in TB treatment.

One presentation will include clinical trial updates on various regimens. These clinical trial updates will include drugs being examined for uses that currently are unlabeled/investigational. This includes trials for which the non-profit organization, TB Alliance, is currently a sponsor, as well as trials that are sponsored by other organizations. The presentation by Shelly Malhotra will disclose where trial updates reflect 1) TB Alliance regimens; 2) where trials reflect study of unlabeled uses of currently available drugs or of investigational drugs.

CONTENT DISCLAIMER

The views expressed in this activity are those of the faculty. It should not be inferred or assumed that they are expressing the views of any manufacturer of pharmaceuticals or devices, or Rutgers. It should be noted that the recommendations made herein with regard to the use of therapeutic agents, varying disease states, and assessments of risk, are based upon a combination of clinical trials, current guidelines, and the clinical practice experience of the participating presenters. The drug selection and dosage information presented in

this activity are believed to be accurate. However, participants are urged to consult all available data or procedures before using them in clinical practice. Rutgers reserves the right to modify the activity content and faculty if necessary.

COPYRIGHT

Copyright[©]2019 Rutgers, The State University of New Jersey. All rights reserved including translation into other languages. No part of this activity may be reproduced or transmitted in any form or by any means, electronic or mechanical, including photocopying, recording, or any information storage and retrieval systems, without permission in writing from Rutgers.

Please direct continuing education related questions to CCOE at 973-972-4267 or email ccoe@ca.rutgers.edu.

Please direct content or course related questions to Amy Lewis 973-972-0978 or email lewisa1@rutgers.edu.

FUNDING DISCLOSURE

Funding for this conference was made possible in part by the Centers for Disease Control and Prevention. The views expressed in written conference materials or publications and by speakers and moderators do not necessarily reflect the official policies of the Department of Health and Human Services, nor does the mention of trade names, commercial practices, or organizations imply endorsement by the U.S. government.